

Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G6DBF5DE978EEN.html>

Date: March 2023

Pages: 100

Price: US\$ 3,660.00 (Single User License)

ID: G6DBF5DE978EEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the "Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Forecast" looks at past sales and reviews total world Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections sales in 2022, providing a comprehensive analysis by region and market sector of projected Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections sales for 2023 through 2029. With Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections industry.

This Insight Report provides a comprehensive analysis of the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections and breaks down the forecast by type, by application, geography, and market

size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections.

The global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections players cover Eli Lilly, Wockhardt Ltd, Amprologix Ltd, CrystalGenomics Inc, Debiopharm International SA, Destiny Pharma Plc, Lysimmune BioScience, Roivant Sciences Ltd and TGV-Inhalonix Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Injection

Pills

Segmentation by application

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Wockhardt Ltd

Amprologix Ltd

CrystalGenomics Inc

Debiopharm International SA

Destiny Pharma Plc

Lysimmune BioScience

Roivant Sciences Ltd

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2018-2029

2.1.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size CAGR by Region 2018 VS 2022 VS 2029

2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Type

2.2.1 Injection

2.2.2 Pills

2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type

2.3.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size CAGR by Type (2018 VS 2022 VS 2029)

2.3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2018-2023)

2.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Other

2.5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application

2.5.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size CAGR by Application (2018 VS 2022 VS 2029)

2.5.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market

Size Market Share by Application (2018-2023)

3 VANCOMYCIN-RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS MARKET SIZE BY PLAYER

3.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size
Market Share by Players

3.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Revenue by Players (2018-2023)

3.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Revenue Market Share by Players (2018-2023)

3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key
Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 VANCOMYCIN-RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS BY REGIONS

4.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by
Regions (2018-2023)

4.2 Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Size Growth (2018-2023)

4.3 APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Size Growth (2018-2023)

4.4 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Size Growth (2018-2023)

4.5 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)
Infections Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Size by Country (2018-2023)

5.2 Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Size by Type (2018-2023)

5.3 Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2018-2023)

6.2 APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2018-2023)

6.3 APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Country (2018-2023)

7.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2018-2023)

7.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections by Region (2018-2023)

8.2 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections Market Size by Type (2018-2023)

8.3 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL VANCOMYCIN-RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS MARKET FORECAST

10.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Regions (2024-2029)

10.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Regions (2024-2029)

10.1.2 Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast

10.1.3 APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast

10.1.4 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast

10.1.5 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast

10.2 Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Country (2024-2029)

10.2.1 United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.2.2 Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.2.3 Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Forecast

10.2.4 Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.3 APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Region (2024-2029)

10.3.1 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.3.2 Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.3.3 Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.3.4 Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.3.5 India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.3.6 Australia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.4 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Country (2024-2029)

10.4.1 Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.4.2 France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.4.3 UK Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.4.4 Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.4.5 Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.5 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Region (2024-2029)

10.5.1 Egypt Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.5.2 South Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.5.3 Israel Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

10.5.4 Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast

- 10.5.5 GCC Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast
- 10.6 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Type (2024-2029)
- 10.7 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Eli Lilly

- 11.1.1 Eli Lilly Company Information
- 11.1.2 Eli Lilly Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
- 11.1.3 Eli Lilly Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Eli Lilly Main Business Overview
- 11.1.5 Eli Lilly Latest Developments

11.2 Wockhardt Ltd

- 11.2.1 Wockhardt Ltd Company Information
- 11.2.2 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
- 11.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Wockhardt Ltd Main Business Overview
- 11.2.5 Wockhardt Ltd Latest Developments

11.3 Amprologix Ltd

- 11.3.1 Amprologix Ltd Company Information
- 11.3.2 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
- 11.3.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
- 11.3.4 Amprologix Ltd Main Business Overview
- 11.3.5 Amprologix Ltd Latest Developments

11.4 CrystalGenomics Inc

- 11.4.1 CrystalGenomics Inc Company Information
- 11.4.2 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
- 11.4.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)

- 11.4.4 CrystalGenomics Inc Main Business Overview
- 11.4.5 CrystalGenomics Inc Latest Developments
- 11.5 Debiopharm International SA
 - 11.5.1 Debiopharm International SA Company Information
 - 11.5.2 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
 - 11.5.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Debiopharm International SA Main Business Overview
 - 11.5.5 Debiopharm International SA Latest Developments
- 11.6 Destiny Pharma Plc
 - 11.6.1 Destiny Pharma Plc Company Information
 - 11.6.2 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
 - 11.6.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Destiny Pharma Plc Main Business Overview
 - 11.6.5 Destiny Pharma Plc Latest Developments
- 11.7 Lysimmune BioScience
 - 11.7.1 Lysimmune BioScience Company Information
 - 11.7.2 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
 - 11.7.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Lysimmune BioScience Main Business Overview
 - 11.7.5 Lysimmune BioScience Latest Developments
- 11.8 Roivant Sciences Ltd
 - 11.8.1 Roivant Sciences Ltd Company Information
 - 11.8.2 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
 - 11.8.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Roivant Sciences Ltd Main Business Overview
 - 11.8.5 Roivant Sciences Ltd Latest Developments
- 11.9 TGV-Inhalonix Inc
 - 11.9.1 TGV-Inhalonix Inc Company Information
 - 11.9.2 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered
 - 11.9.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections Revenue, Gross Margin and Market Share (2018-2023)

11.9.4 TGV-Inhalonix Inc Main Business Overview

11.9.5 TGV-Inhalonix Inc Latest Developments

11.10 Therapeutic Systems Research Laboratories Inc

11.10.1 Therapeutic Systems Research Laboratories Inc Company Information

11.10.2 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

11.10.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, Gross Margin and Market Share (2018-2023)

11.10.4 Therapeutic Systems Research Laboratories Inc Main Business Overview

11.10.5 Therapeutic Systems Research Laboratories Inc Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 2. Major Players of Injection
- Table 3. Major Players of Pills
- Table 4. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2018-2023) & (\$ Millions)
- Table 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2018-2023)
- Table 7. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 8. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2018-2023) & (\$ Millions)
- Table 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2018-2023)
- Table 10. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Players (2018-2023) & (\$ Millions)
- Table 11. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Player (2018-2023)
- Table 12. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Players Head office and Products Offered
- Table 13. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- Table 14. New Products and Potential Entrants
- Table 15. Mergers & Acquisitions, Expansion
- Table 16. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Regions 2018-2023 & (\$ Millions)
- Table 17. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Regions (2018-2023)
- Table 18. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 19. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Country/Region (2018-2023)
- Table 20. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size by Country (2018-2023) & (\$ Millions)

Table 21. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Country (2018-2023)

Table 22. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Type (2018-2023)

Table 24. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Application (2018-2023)

Table 26. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Region (2018-2023)

Table 28. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Type (2018-2023)

Table 30. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Application (2018-2023)

Table 32. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Country (2018-2023)

Table 34. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Type (2018-2023)

Table 36. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)
Infections Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)
Infections Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Table 45. Key Market Challenges & Risks of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Table 46. Key Industry Trends of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Table 47. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. Eli Lilly Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 52. Eli Lilly Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 53. Eli Lilly Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. Eli Lilly Main Business

Table 55. Eli Lilly Latest Developments

Table 56. Wockhardt Ltd Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 57. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 58. Wockhardt Ltd Main Business

Table 59. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Wockhardt Ltd Latest Developments

Table 61. Amprologix Ltd Details, Company Type, Vancomycin-Resistant

Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 62. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 63. Amprologix Ltd Main Business

Table 64. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 65. Amprologix Ltd Latest Developments

Table 66. CrystalGenomics Inc Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 67. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 68. CrystalGenomics Inc Main Business

Table 69. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 70. CrystalGenomics Inc Latest Developments

Table 71. Debiopharm International SA Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 72. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 73. Debiopharm International SA Main Business

Table 74. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 75. Debiopharm International SA Latest Developments

Table 76. Destiny Pharma Plc Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 77. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 78. Destiny Pharma Plc Main Business

Table 79. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 80. Destiny Pharma Plc Latest Developments

Table 81. Lysimmune BioScience Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 82. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 83. Lysimmune BioScience Main Business

Table 84. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 85. Lysimmune BioScience Latest Developments

Table 86. Roivant Sciences Ltd Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 87. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 88. Roivant Sciences Ltd Main Business

Table 89. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Roivant Sciences Ltd Latest Developments

Table 91. TGV-Inhalonix Inc Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 92. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 93. TGV-Inhalonix Inc Main Business

Table 94. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. TGV-Inhalonix Inc Latest Developments

Table 96. Therapeutic Systems Research Laboratories Inc Details, Company Type, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Area Served and Its Competitors

Table 97. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offered

Table 98. Therapeutic Systems Research Laboratories Inc Main Business

Table 99. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. Therapeutic Systems Research Laboratories Inc Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country/Region (2022)

Figure 8. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type in 2022

Figure 10. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in Hospital

Figure 11. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market: Hospital (2018-2023) & (\$ Millions)

Figure 12. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in Clinic

Figure 13. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market: Clinic (2018-2023) & (\$ Millions)

Figure 14. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in Other

Figure 15. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market: Other (2018-2023) & (\$ Millions)

Figure 16. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application in 2022

Figure 17. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Player in 2022

Figure 18. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Regions (2018-2023)

Figure 19. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2018-2023 (\$ Millions)

Figure 20. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Value Market Share by Country in 2022

Figure 24. United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Region in 2022

Figure 29. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type in 2022

Figure 30. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application in 2022

Figure 31. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Country in 2022

Figure 38. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2018-2023)

Figure 39. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2018-2023)

Figure 40. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 42. UK Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 43. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 44. Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 57. United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 61. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections Market Size 2024-2029 (\$ Millions)

Figure 65. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 68. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 69. UK Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Size 2024-2029 (\$ Millions)

Figure 70. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA)

Infections Market Size 2024-2029 (\$ Millions)

Figure 78. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G6DBF5DE978EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6DBF5DE978EEN.html>